Physician profile
Daniel S Voss
NPI 1639259625
$4,662.98
in general payments reported to CMS, 2019-2025
41 companies · $31.03 in 2025
The $31.03 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,411 · 2020: $925 · 2021: $1,453 · 2022: $722 · 2023: $93.18 · 2024: $26.81 · 2025: $31.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $776.82 | 2019-2022 | |
| Amarin Pharma, INC. | $396.20 | 2019-2021 | |
| Glaxosmithkline, LLC. | $346.67 | 2019-2022 | |
| Amgen INC. | $309.41 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $294.13 | 2019-2022 | |
| Allergan, INC. | $288.69 | 2019-2020 | |
| Abbvie INC. | $281.16 | 2019-2022 | |
| Abbott Laboratories | $260.61 | 2019-2025 | Freestyle Libre 3, Proclaim |
| Lilly USA, LLC | $199.67 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $130.04 | 2019-2021 | |
| Esperion Therapeutics, INC. | $115.41 | 2020-2021 | |
| Astellas Pharma US INC | $109.01 | 2019-2021 | |
| Mylan Specialty L.P. | $99.59 | 2020-2022 | |
| Biohaven Pharmaceuticals, INC. | $84.81 | 2021 | |
| Pfizer INC. | $82.19 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Voss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.